\nTakeda Pharmaceutical Company Limited (TSE:4502\/NYSE:TAK<\/a><\/b>) (\u201cTakeda\u201d) today announced the addition of four partnerships to its Global Corporate Social Responsibility (CSR) Program<\/a>, which makes long-term commitments to strengthen health systems and improve access to healthcare for all in developing and emerging countries. As part of an annual decision-making process, Takeda employees worldwide voted to add IntraHealth International<\/i>, Jhpiego<\/i>, Pathfinder International<\/i> and the World Food Programme<\/i>(WFP)<\/i> as new partners for the Global CSR Program, which now supports 20 programs in 72 countries.\n<\/p>\n
\nTakeda\u2019s commitments to these new partners in FY2021 include:\n<\/p>\n
- \n
- JPY 953 million to IntraHealth International <\/i><\/b>to work with 12 private schools in Mali, Senegal and Niger to increase the number of qualified, trained nurses who can serve rural communities facing a critical shortage of health workers in these countries. Over the next five years, the project will help private schools partner with the public sector, achieve the appropriate accreditations, enhance competency-based curricula, create effective learning approaches and graduate students from underserved areas\u2014all as part of the effort to ensure that everyone everywhere has access to healthcare.\n<\/li>\n
- JPY 890 million to Jhpiego\u2019s<\/i><\/b> iWIN project, to help accelerate progress in preventing maternal and newborn mortality and morbidity by mending the fragmented maternal and child health ecosystem in India via a holistic, woman-centered approach. Over the next five years, the project will catalyze adoption of an Indian-owned model to continuously track and utilize ground-breaking information on the health of pregnant women to create a sustainable, next generation approach to coordinated, patient-centered care before, during and post pregnancy.\n<\/li>\n
- JPY 1 billion to Pathfinder International<\/i><\/b> to advance women\u2019s and girls\u2019 leadership in responding to the disproportionate impact of climate change and emergencies on women\u2019s health. Operating in South and Southeast Asia over four years, the project will position women and girls as change agents in places where gender inequalities and climate-related crises reduce their quality of health. The project will strengthen access to equitable health services, build community resilience to climate shocks and help women forge their own path to a healthier future.\n<\/li>\n
- JPY 1.3 billion to the<\/i>World Food Programme\u2019s<\/i><\/b> Project Boreas, over the next five years. The project will enhance the capacity of the United Nations Humanitarian Response Depot in Accra, Ghana, to more efficiently receive, store and transport temperature-sensitive health products in 17 countries in West Africa. The project will create a regional Logistics Knowledge Centre where supply chain professionals and national governments can receive training on best-in-class supply chain practices, ensuring that they are better equipped to face and manage health emergencies.\n<\/li>\n<\/ul>\n
\n\u201cWe at IntraHealth are thrilled to be partnering with Takeda to address the shortage of highly trained nurses in rural communities in Mali, Senegal and Niger. This partnership will revolutionize health worker training at private nursing schools, improve health care in the communities that need it most and attract more brilliant young students to the profession,\u201d said Polly Dunford, president and CEO of IntraHealth International.\n<\/p>\n
\n\u201cJhpiego is humbled and excited to have won the confidence of Takeda\u2019s employees to implement the Integrated Women in Health Network (iWIN) project in Madhya Pradesh, India. It is incredibly inspiring to be motivated by a shared belief: that all women deserve access to the high-quality pregnancy care that saves lives. Together, we will build a mother-focused, scalable maternal and newborn health system by raising quality and continuity of care and leveraging predictive analytics and innovative financing,\u201d said Leslie Mancuso, president and CEO of Jhpiego.\n<\/p>\n
\n\u201cPathfinder is honored to work with Takeda to advance the leadership of women and girls. This project is a living example of Takeda\u2019s commitment to better health for people and a brighter future for the world. We will elevate women\u2019s leadership in South and Southeast Asia for improved health and climate resilience,\u201d said Lois Quam, president and CEO of Pathfinder International.\n<\/p>\n
\n\u201cThe World Food Programme is honored to have been chosen by Takeda\u2019s employees as part of their Global CSR Program for a project that is so timely and important. The COVID-19 pandemic served as an important reminder of the need for countries to be prepared for, and equipped to respond to, health emergencies. With Takeda\u2019s help, we aim to provide critical support in 17 countries across West Africa \u2013 safeguarding vulnerable communities and building capacity for the future,\u201d said Tim Hunter, director of Private Partnerships and Fundraising at WFP.\n<\/p>\n
\nSince launching in 2016, Takeda\u2019s signature Global CSR Program has committed a total of 16.5 billion yen to 17 international and non-governmental organizations on 20 long-term projects that address more than 23 Sustainable Development Goal (SDG) Targets in 72 countries. Each project addresses strengthening health systems in unique ways and aligns with countries\u2019 national health needs. These four- to 10-year funding commitments reflect that sustainable impact takes time and there are no quick fixes to the complex and longstanding challenges that health systems face.\n<\/p>\n
\n\u201cWe are proud to partner with IntraHealth International, Jhpiego, Pathfinder International and the World Food Programme to increase the number of qualified health workers, transform supply chains, address the impact of climate change, conflict and emergencies on women\u2019s health, and leverage data and digital to transform maternal and newborn care,\u201d said Takako Ohyabu, Takeda chief global corporate affairs officer. \u201cAll our new partnerships address endemic challenges health systems face today while empowering communities to be ready for the future.\u201d\n<\/p>\n
\nTakeda\u2019s Global CSR Program partnerships have made notable progress since 2016:\n<\/p>\n
- \n
- \nReached more than 5.84 million direct beneficiaries;\n<\/li>\n
- \nTrained more than 32,000 qualified health workers;\n<\/li>\n
- \nProvided more than 570,000+ community members with targeted health education;\n<\/li>\n
- \nImmunized millions of children against preventable diseases such as measles; and\n<\/li>\n
- Our partners<\/a> are on track to reach 18.4 million direct beneficiaries by 2027, providing lifesaving care for vulnerable women and newborns, preventing stunting, strengthening holistic support for refugees, and so much more.\n<\/li>\n<\/ul>\n
About Takeda Pharmaceutical Company Limited<\/b><\/p>\n
\nTakeda Pharmaceutical Company Limited (TSE: 4502\/NYSE: TAK<\/a>) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people\u2019s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https:\/\/www.takeda.com<\/a>.\n<\/p>\n
Important Notice<\/b><\/p>\n
\nFor the purposes of this notice, \u201crelease\u201d means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (\u201cTakeda\u201d) regarding this release. This release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this release, \u201cTakeda\u201d is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words \u201cwe\u201d, \u201cus\u201d and \u201cour\u201d are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.\n<\/p>\n
Forward-Looking Statements<\/b><\/p>\n
\nThis press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda\u2019s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as \u201ctargets\u201d, \u201cplans\u201d, \u201cbelieves\u201d, \u201chopes\u201d, \u201ccontinues\u201d, \u201cexpects\u201d, \u201caims\u201d, \u201cintends\u201d, \u201censures\u201d, \u201cwill\u201d, \u201cmay\u201d, \u201cshould\u201d, \u201cwould\u201d, \u201ccould\u201d \u201canticipates\u201d, \u201cestimates\u201d, \u201cprojects\u201d or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda\u2019s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda\u2019s operations and the timing of any such divestment(s); and other factors identified in Takeda\u2019s most recent Annual Report on Form 20-F and Takeda\u2019s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda\u2019s website at: https:\/\/www.takeda.com\/investors\/sec-filings\/<\/a> or at www.sec.gov<\/a>. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda\u2019s future results.\n<\/p>\n
<\/p>\n
View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210922005634\/en\/<\/a><\/span><\/p>\n
Media Contacts:
\n<\/b>
Japanese Media
\n<\/b>
Ryoko Matsumoto
\n
ryoko.matsumoto@takeda.com
\n<\/a>
+81 (0) 3-3278-3414<\/p>\nMedia Outside Japan
\n<\/b>
Christina Beckerman
\n
christina.beckerman@takeda.com
\n<\/a>
+1 781-482-0831\n<\/p>\nKEYWORDS:<\/b> Japan Asia Pacific<\/p>\n
INDUSTRY KEYWORDS:<\/b> Philanthropy Health Other Philanthropy General Health Pharmaceutical Biotechnology<\/p>\n
- JPY 890 million to Jhpiego\u2019s<\/i><\/b> iWIN project, to help accelerate progress in preventing maternal and newborn mortality and morbidity by mending the fragmented maternal and child health ecosystem in India via a holistic, woman-centered approach. Over the next five years, the project will catalyze adoption of an Indian-owned model to continuously track and utilize ground-breaking information on the health of pregnant women to create a sustainable, next generation approach to coordinated, patient-centered care before, during and post pregnancy.\n<\/li>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20210922005634\/en\/908603\/3\/Dakiyama_2021_Takeda_Red_DIGITAL_USE.jpg\")
<\/td>\n<\/tr>\n